NSCEB Visits Leading New Jersey Biotech Industry
New Jersey’s best-in-class education systems and biomanufacturing hubs make it a strong driver of the national biotechnology industry
1 August 2025
FOR IMMEDIATE RELEASE
Princeton, New Jersey – Today, the National Security Commission on Emerging Biotechnology (NSCEB) joined Representative Herb Conaway (NJ-03) and hosts from Princeton University, BioNJ, and Amicus Therapeutics to explore the convergence of AI and biotechnology (AIxBio). The group discussed how the Commission’s recommendations and better coordination on federal biotechnology policy can further bolster New Jersey’s biotech workforce and innovation pipeline.
“New Jersey’s biotechnology industry is building great momentum,” said NSCEB Vice Chair Michelle Rozo. “The convergence of AI and biotechnology will be transformative, and New Jersey is poised to be a national leader not only in innovation, but also in building our biomanufacturing capacity and educating the next generation of our biotechnology workforce.”
“The future of American biotechnology depends on how boldly we invest in the tools and talent that will define the next century of innovation,” said Rep. Herb Conaway (NJ-03). “From AI-ready biological datasets to cutting-edge startups and biomanufacturing hubs like New Jersey, we have the building blocks in place, we just need to align our national strategy. Today’s event and discussion is about making sure every zip code in our country has a seat at the table in shaping that future.”
Today’s event highlighted the impact that AIxBio is having on the broader biotechnology ecosystem and how the U.S. can lean into its inherent advantages in venture capital, medical research, and biotech talent to further accelerate innovation and economic growth.
The event took place at Princeton University where the Omenn-Darling Bioengineering Institute serves as a bridge between engineering and the life sciences, to advance innovation and develop the next generation of bioengineering leaders. Event cohosts included BioNJ, the statewide, non-profit association that acts as an advocate to spur economic collaboration, and Amicus Therapeutics, a New Jersey-based biotechnology company focused on therapies for rare diseases.
“Princeton is investing heavily in bioengineering, and training the biotech talent of the future,” said Dr. Clifford Brangwynne. “As Director of Princeton’s new Omenn-Darling Bioengineering Institute, I am thrilled that we’ve brought together stakeholders from government, industry, and academia to discuss how biotechnology can advance the strategic and economic interests of New Jersey and the U.S.”
“To maintain U.S. leadership and address the 95% of rare diseases still without treatments, we must recommit to innovation, streamline drug development, and strengthen domestic manufacturing and jobs amid rising global competition,” said Bradley Campbell, President and CEO of Amicus Therapeutics. “The bipartisan National Security Commission on Emerging Biotechnology has provided a clear roadmap. I look forward to partnering with state and federal leaders to ensure America remains at the forefront of this vital industry, advancing lifesaving breakthroughs and securing our nation’s health and economic future for generations to come.”
Event participants included:
- New Jersey State Senator Andrew Zwicker
- Amicus Therapeutics
- Bristol Meyers Squibb
- Cellares
- CEO Roundtable on Cancer
- United States Representative Herb Conaway
- IBM
- IQVIA
- NJ AI Hub
- New Jersey Department of Workforce and Labor
- New Jersey Economic Development Authority
- Omenn-Darling Bioengineering Institute
- Princeton University
Biotech Across America Roadshow
This summer, the Commission is hitting the road to highlight biotechnology across America, including the companies, academic institutions, workforce development programs, and policy initiatives that are driving the future for this rapidly growing industry. Commissioners will continue learning about the work being done across this vibrant ecosystem while engaging on the key findings and recommendations from the Commission’s recent report to Congress.
About NSCEB: The National Security Commission on Emerging Biotechnology is a time-limited, high-impact legislative branch advisory entity whose purpose is to advance and secure biotechnology, biomanufacturing, and associated technologies for U.S. national security and to prepare the United States for the bioindustrial revolution. The Commission published a comprehensive report in April 2025, including recommendations for action by Congress and the federal government. The bipartisan Commission is composed of Congressionally-appointed Commissioners with members from both the Senate and the House of Representatives as well as experts from industry, academia, and government. For more information about the Commission and to view the report, visit biotech.senate.gov.
Contacts:
NSCEB: press@biotech.senate.gov
